Neogen (FRA:NG2) Stock Based Compensation: €12.8 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NG2 Neogen Corp FRA:NG2
69 GF Score
Price €8.88
GF Value €10.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neogen Stock Based Compensation?

Neogen FRA:NG2 +3.67% 69 Stock Based Compensation is €12.8 Mil as of Feb. 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 69/100 and a GF Value™ of €10.62 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Neogen's Stock Based Compensation for the three months ended in Feb. 2026 was €0.9 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Feb. 2026 was €12.8 Mil.

Neogen Stock Based Compensation Related Terms

Neogen Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Neogen's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neogen Stock Based Compensation Chart

Neogen Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.30 6.77 9.36 12.74 15.34

Neogen Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.03 3.81 4.26 3.75 0.93
FRA:NG2
69GF Score
Neogen Corp FRA:NG2
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neogen Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.8 Mil.

What does a Stock Based Compensation of €12.8 Mil mean?
Neogen (FRA:NG2) has a Stock Based Compensation of €12.8 Mil as of Feb. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Neogen and its competitors.
Is Neogen's Stock Based Compensation too high?
Neogen's current Stock Based Compensation is €12.8 Mil. Overall, Neogen has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Stock Based Compensation compare to UFPT and ALMR?
Neogen's Stock Based Compensation of €12.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Neogen and its competitors. Neogen's current Stock Based Compensation is €12.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.62, compared to a current price of €8.88 — trading 16.4% below its estimated fair value. The current Stock Based Compensation is €12.8 Mil. Neogen's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Stock Based Compensation is €12.8 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neogen (FRA:NG2) Overvalued in 2026?

Based on GuruFocus' analysis, Neogen stock appears to be undervalued. The current stock price of €8.88 is trading 16.4% below its estimated GF Value™ of €10.62. GuruFocus considers Neogen to be Modestly Undervalued.

Key valuation signals for FRA:NG2:

  • Stock Based Compensation: €12.8 Mil
  • GF Value™: €10.62 vs. price of €8.88 (16.4% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neogen Business Description

Other Exchanges NEOG:USANG2:Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
69GF Score

Get the complete analysis for FRA:NG2

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.88
Price
€10.62
GF Value